Muscular Dystrophies and Allied Disorders III: Congenital Muscular Dystrophies and Associated Disorders

History and Background The term ‘congenital muscular dystrophy’ (CMD) has been widely used to describe a group of infants with weakness and hypotonia from birth or within the first few months of life. Severe, early contractures are common, and most cases have delayed motor milestones. Detailed clinical studies combined with pathological and molecular studies have revolutionized this field and led to the characterization of several conditions…

Muscular Dystrophies and Allied Disorders II: Limb-Girdle Muscular Dystrophies

History and Background Heterogeneity in the muscular dystrophies has long been recognized ( ). The wide application of molecular techniques and increasing use of next-generation sequencing have identified a growing number of clinical entities, and their gene and protein defects, described as ‘limb-girdle muscular dystrophies’ (LGMD). This is a diverse group of disorders with either autosomal dominant or autosomal recessive inheritance ( Tables 11.1 and 11.2…

Muscular Dystrophies and Allied Disorders I: Duchenne and Becker Muscular Dystrophy

Background Although the advent of molecular genetics has transformed the diagnostic confirmation of Duchenne and Becker muscular dystrophy, we thought it worth retaining some historical background and clinical description of these classical muscular disorders. Duchenne muscular dystrophy (DMD) has been recognized as a clinical entity since the 19th century. In 1868, Duchenne gave a detailed account of 13 male patients with progressive muscle weakness ( ).…

Neurogenic Disorders

There are many inherited and acquired clinical disorders caused by a defect in upper or lower motor neurone or the peripheral nerve. These include amyotrophic lateral sclerosis (ALS; upper and lower motor neurone), hereditary motor and sensory neuropathies (HMSNs; motor and sensory neurone and peripheral nerves), the spinal muscular atrophies (SMAs; lower motor neurone) and inflammatory peripheral neuropathies. In addition, ageing of muscle, some metabolic conditions,…

How to Read a Biopsy

When the pathologist is asked to evaluate a muscle biopsy, much of the interpretation is based on his or her previous experience and the recognition of similarities between the biopsy and muscle from known diseases. In some instances, such as an advanced dystrophy or a spinal muscular atrophy, the changes may be striking and unequivocal. In others, the changes may be more subtle and a systematic…

Immunohistochemistry and Immunoblotting

Immunohistochemistry Immunohistochemistry has an essential role in the evaluation of muscle biopsies and in examining protein localization. The term ‘protein expression’ is often applied to describe immunohistochemical results, but it should be remembered that the technique only reflects localization of a protein, not the related RNA synthesis, and the gene coding for it may not be active at the time the protein is localized. In addition,…

Ultrastructural Changes

Skeletal muscle undergoes many changes in response to disease and trauma. With the electron microscope, the abnormalities seen at the light level can be characterized and accurately localized, and the variety of changes affecting each organelle identified. The interpretation of the pathological abnormalities observed in a muscle biopsy must take into account several factors, in particular the small sample size, possible artefacts induced by preparation and…

Histological and Histochemical Changes

This chapter deals with the various changes that may occur in a muscle under pathological conditions. As we show, very few abnormalities are in themselves pathognomonic of a particular disease. However, by evaluating the constellation of different changes that are present within a given biopsy, and assessing these in the context of clinical features of the patient, one can often obtain a fairly accurate diagnosis. To…

Normal Muscle

In this chapter, the composition and appearance of normal muscle will be discussed. The first part will be concerned with the anatomical constituents of normal muscle at the light microscope level, followed by histochemical aspects of the different types of muscle fibres and ultrastructural details of muscle. We then discuss myogenesis and the development of muscle. Histological Structure The word muscle is derived from the Latin…

Histological and Histochemical Stains and Reactions

Just as every pathologist has particular preferences for routine stains, so muscle histochemists have tended to develop preferences for particular reactions, especially in the interpretation of fibre types. In the early days of the application of histochemical techniques to the study of muscle, large batteries of enzymes were routinely studied in muscle biopsies (see ). While these many enzyme reactions were of special interest and value…

The Procedure of Muscle Biopsy

The Evolving Role of Muscle Pathology Muscle biopsy has been an important part of the assessment of patients with a neuromuscular disorder for many decades. The use of frozen sections and the application of histochemistry and electron microscopy have identified many pathological features that have defined and diagnosed a disorder. The molecular genetic revolution that began with the discovery of the gene responsible for Duchenne muscular…

Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy : A Resource Review

Introduction According to the World Cancer Research Fund (WCRF) there were 279,000 cases of pancreatic cancer diagnosed worldwide in 2008 ( ). The estimated five-year prevalence of people living with pancreatic cancer is projected at 3.5% per 100,000 and it is the 13th most common cancer in the world. Pancreatic cancer is almost always fatal and is the eighth leading cause of cancer-related deaths in…

Computational and Biological Evaluation of Radioiodinated Quinazolinone Prodrug for Targeting Pancreatic Cancer

Introduction to EMCIT Concept The concept of enzyme-mediated cancer imaging and therapy (EMCIT) involves the use of an enzyme specifically overexpressed on the surface of cancer cells. As such, the enzyme can act as a mediator for the hydrolysis of a soluble, radioisotopically labeled prodrug to a water-insoluble drug. This enzyme-dependent and site-specific hydrolysis provides a noninvasive technique for imaging and therapy, based on the rapid…

Integration of Protein Network Activation Mapping Technology for Personalized Therapy: Implications for Pancreatic Cancer

Introduction The underpinning and ultimate promise of personalized therapy is that the molecular fingerprint of a patient’s tumor becomes the rationale for targeted and patient-tailored therapy. Until recently, this fingerprint has been a genomics-centered analysis using exome panels, whole genome sequencing, and/or RNA sequencing comprising the details that most scientists and treating oncologists consider when considering a “precision medicine”–based approach. Stratification and selection of patients for…

Prioritizing Diagnostic, Prognostic, and Therapeutic MicroRNAs in Pancreatic Cancer: Systems and Network Biology Approaches

An Introduction and Brief Overview of MicroRNAs MicroRNAs (miRNAs) are short noncoding RNAs 22 nucleotides in length that carry out complex regulatory functions through post-transcriptional targeting and modification. Initially, these miRNAs were discovered through analyses of Caenorhabditis elegans development, in which it was shown that the lin-4 and let-7 antisense RNAs exhibited developmental regulatory function in the organism post-transcriptionally . The miRNAs are exported from the…

Characterizing the Metabolomic Effects of Pancreatic Cancer

Introduction Pancreatic cancer is the fourth most common cause of cancer death in North America. The five-year survival rate is only 5.1% . The high lethality related to pancreatic cancer is due to a number of factors. It is biologically aggressive, it has profound effects on the host, and it is resistant to most cytotoxic agents. Moreover, early diagnosis is infrequent, and so resection (which represents…

Systems Biology of Pancreatic Cancer Stem Cells

Acknowledgment We acknowledge Dr Fazlul Sarkar for providing the necessary reagents (CSCs) to conduct the studies described in this chapter. Introduction Pancreatic cancer (PC) kills ∼300,000 individuals worldwide, and each year in the United States there are an estimated 43,920 new diagnoses with an annual mortality of 37,390 . It is one of the most difficult cancers to treat, with a five-year survival (<5%) due in…

The Significance of the Feedback Loops between Kras and Ink4a in Pancreatic Cancer

Introduction Molecular feedback mechanisms lend robustness and the ability of living cells to respond and adapt to their environment. As a means to ward off cancer, for example, the expression of proto-oncogenes in response to growth factors is normally followed by the expression of tumor suppressor genes. Myc and p53—a proto-oncogene and a tumor suppressor gene, respectively—are good examples of genes with concomitant expressions; and, in…

RNAi Validation of Pancreatic Cancer Antigens Identified by Cell Surface Proteomics

Acknowledgments The authors wish to thank Jenny L. Heidbrink, Victoria Bushman, Erin Brand, Jim Norton, Jun Kim, Brian Feild, Roxanne Armstrong, Henrik Olsen, Will Fitzhugh, Jim Duff, Ping Zhang and Katherine Paweletz, for their technical assistance. We also wish to thank Samuel Broder, Robert Booth and Scott Patterson for their advise on this project. Introduction Unlike most other cancers, incidences of pancreatic cancer have been on…